Alzchem beats Q1 earnings despite sales miss on steel weakness

Alzchem Q1 results were mixed but slightly better than expected, with EPS of €1.77 beating consensus by 7% and EBITDA of €32.3 million topping estimates by 6%, even as sales of €148.7 million missed by 1%. Management confirmed full-year 2026 guidance for about €600 million in sales and €126 million in EBITDA, implying growth of 7% and 8%, respectively, and reiterated low-double-digit growth from 2027 onward. The main drag remains weakness in Europe’s steel-linked Basic and Intermediates segment, though Specialty Chemicals continued to perform well.

Analysis

This print reinforces that the equity story is increasingly a volume-and-capacity story, not a macro-beta story. The key signal is that pricing power is still intact in the high-value specialty franchises, which means the market should underwrite a higher quality of earnings than the headline steel-linked weakness suggests. The negative working-capital and capex drag is also a tell: management is deliberately converting current demand into future capacity, so near-term free cash flow can stay noisy while the longer-dated earnings power steps up.

The second-order winner is not the company’s legacy exposure, but the adjacent supply chain around high-spec industrial chemicals where constrained capacity tends to support pricing for longer than consensus expects. The biggest loser is any competitor relying on older, commoditized European production assets: they face weaker utilization, less pricing discipline, and likely margin compression if Alzchem keeps adding capacity into a better product mix. That creates a subtle competitive moat widening effect over the next 12-24 months as the mix shifts further toward specialty end-markets.

The main risk is that the market may extrapolate this beat linearly and ignore timing mismatch: revenue growth is being pulled forward by pricing and mix, while incremental cash conversion is delayed by investment. If European industrial demand deteriorates further, the basic/intermediates weakness can bleed into sentiment and obscure the specialty upside. The catalyst path is clear though: commissioning milestones in 2H26 and 2H27 should re-rate the stock if they arrive on schedule, because each milestone de-risks the medium-term growth algorithm.

Consensus is probably underappreciating how much of the value is optionality on capacity expansion rather than the current quarter. The stock should trade on forward margin expansion and volume elasticity in creatine/nitroguanidine, not on near-term free cash flow alone. If management continues to confirm guidance while the mix improves, the multiple can rerate before the actual capacity comes online.

Key Decisions for Investors

• Long ACT GR on any post-earnings consolidation over the next 1-3 weeks; risk/reward favors buying weakness because the market is likely to underwrite 2027 capacity before the cash flow inflection shows up.
• Pair trade: long ACT GR / short a European basic chemicals or steel-linked proxy for the next 3-6 months; the thesis is that specialty mix and capacity expansion outgrow cyclical end-market exposure.
• Add on confirmation of 2H26 nitroguanidine commissioning; treat that milestone as a de-risking event that should support a rerating into the 6-12 month window.
• If using options, structure a 6-12 month call spread on ACT GR to express upside from guidance confirmation and capacity catalysts while limiting exposure to near-term working-capital noise.
• Do not chase a full-size position on the headline beat alone; wait for evidence that specialty volume momentum persists for 1-2 quarters, otherwise the stock can mean-revert if Europe softens further.